Third Harmonic Bio receives stockholder approval of plan of liquidation

Third Harmonic Bio (THRD) announced that its stockholders overwhelmingly approved the previously proposed Plan of Liquidation and Dissolution at the Company’s Annual Meeting of Stockholders held on June 5, 2025. In addition, The Company also announced the results of a recently completed additional cohort in its Phase 1 clinical trial of its oral wild-type KIT inhibitor development candidate, THB335, and that it is initiating the sale process of THB335 as part of the Plan of Dissolution. Subject to final approval by its Board of Directors, the Company currently expects to finalize the Plan of Dissolution and make the initial distribution to stockholders in the third quarter of 2025. The proposal to adopt the Plan of Dissolution received the affirmative vote of holders of 99.9% of the shares casting votes and 83.7% of the Company’s total outstanding common shares. Based on the information currently available to the Company, the Company estimates that the total distributions will be in the range between approximately $5.30 and $5.44 per share of common stock. The initial distribution, currently expected in the third quarter of 2025, is estimated to be between approximately $5.30 and $5.35 per share of common stock. These estimates do not include cash that may become available for distribution from the proceeds from any sales of the Company’s remaining assets and intellectual property, including but not limited to a sale of THB335. The amount distributable, however, may vary substantially from any estimate provided by the Company based on a number of factors.